Sonya Del Tredici and John Keenan
Sonya Del Tredici and John Keenan
49. Naltrexone/Bupropion for Methamphetamine Use Disorder
49. Naltrexone/Bupropion for Methamphetamine Use Disorder
49. Naltrexone/Bupropion for Methamphetamine Use Disorder
Monday 21st October 2024
Explore new treatments for methamphetamine use disorder with naltrexone and bupropion, plus insights on a promising fentanyl vaccine.
37 minutes
Informative
Engaging
Eye-opening
Educational
Supportive
About this podcast
Author:
Sonya Del Tredici and John Keenan
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Navigating Intimate Relationships
Family Recovery from Addiction
Nutritional Pathways to Recovery
Episodes:
61 (View all)
Do you want to link to this podcast?
Get the buttons here!Breaking Down New Treatments for Methamphetamine Use Disorder
Episode Overview
- Extended-release naltrexone and bupropion show promise in treating methamphetamine use disorder.
- The ADAPT-2 trial reveals significant reductions in methamphetamine use over 12 weeks.
- A new fentanyl vaccine could prevent overdoses by blocking euphoric effects.
- Manufacturing fentanyl is alarmingly easy and accessible.
- Practical advice for integrating new treatments into addiction medicine practice.
More tools in the toolbox is always a good thing.
Ever wondered about the latest treatments for methamphetamine use disorder? In this episode of Addiction Medicine Journal Club, Dr. Sonya Del Tredici and Dr. John Keenan break down the 12-week follow-up data from the ADAPT-2 trial. They explore how extended-release injectable naltrexone and bupropion could be game-changers in reducing methamphetamine use. The discussion is peppered with insights into the practicality of these treatments, especially for those dealing with multiple substance use disorders. But that's not all.
The hosts also dive into a fascinating article about a promising fentanyl vaccine and its potential to prevent overdoses by blocking euphoric effects. Dr. Keenan shares his thoughts on the feasibility of such a vaccine in primary care, considering the challenges of vaccine hesitancy among patients with addiction. The conversation takes an intriguing turn as they discuss how easy it is to manufacture fentanyl, based on an eye-opening investigative piece by Reuters.
You'll be amazed at how accessible the materials are and the global supply chain behind this dangerous drug. Dr. Del Tredici and Dr. Keenan's banter and expertise make complex topics accessible and engaging. Whether you're a healthcare professional or someone interested in addiction treatment, this episode offers valuable perspectives and practical advice. Curious about how these treatments could fit into your practice or personal journey? Tune in to find out!